Nanoparticles comprising anti-programmed cell death 1 (anti-PD-1) as well as anti-OX40 antibodies improved T-cell activation and therapeutic effectiveness in mice with melanoma and breast cancer when compared to therapy with the same drugs given as a straightforward medication combination (39). Here, PDCD1 is linked to breast carcinoma.